234 related articles for article (PubMed ID: 17936447)
1. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1.
Cho HJ; Shin HJ; Han IK; Jung WW; Kim YB; Sul D; Oh YK
Vaccine; 2007 Nov; 25(47):8049-57. PubMed ID: 17936447
[TBL] [Abstract][Full Text] [Related]
2. Protection against human papillomavirus type 16-induced tumors in C57BL/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein.
Taghinezhad-S S; Mohseni AH; Keyvani H; Razavilar V
Microb Pathog; 2019 Jan; 126():149-156. PubMed ID: 30391536
[TBL] [Abstract][Full Text] [Related]
3. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
4. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
[TBL] [Abstract][Full Text] [Related]
5. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
Yan X; Wang D; Liang F; Fu L; Guo C
Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
[TBL] [Abstract][Full Text] [Related]
6. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
7. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
8. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.
Kuck D; Lau T; Leuchs B; Kern A; Müller M; Gissmann L; Kleinschmidt JA
J Virol; 2006 Mar; 80(6):2621-30. PubMed ID: 16501072
[TBL] [Abstract][Full Text] [Related]
9. Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice.
Hongli L; Xukui L; Ting L; Wensheng L; Lusheng S; Jin Z
Hum Vaccin Immunother; 2013 Jan; 9(1):83-9. PubMed ID: 23108357
[TBL] [Abstract][Full Text] [Related]
10. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant.
Oh YK; Sohn T; Park JS; Kang MJ; Choi HG; Kim JA; Kim WK; Ko JJ; Kim CK
Virology; 2004 Oct; 328(2):266-73. PubMed ID: 15464846
[TBL] [Abstract][Full Text] [Related]
11. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
Fraillery D; Zosso N; Nardelli-Haefliger D
Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
[TBL] [Abstract][Full Text] [Related]
12. Immune response to plasmid DNA encoding HPV16-L1 protein.
Sun X; Si L; Cao Z; Wang Y; Liu T; Guo J
Chin Med J (Engl); 2000 Mar; 113(3):277-80. PubMed ID: 11775264
[TBL] [Abstract][Full Text] [Related]
13. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
[TBL] [Abstract][Full Text] [Related]
14. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
[TBL] [Abstract][Full Text] [Related]
15. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
16. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.
Echchannaoui H; Bianchi M; Baud D; Bobst M; Stehle JC; Nardelli-Haefliger D
Infect Immun; 2008 May; 76(5):1940-51. PubMed ID: 18332214
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interleukin 6 with M cell-targeting moiety produced in Lactococcus lactis IL1403 as a potent mucosal adjuvant for peroral immunization.
Li HS; Piao DC; Jiang T; Bok JD; Cho CS; Lee YS; Kang SK; Choi YJ
Vaccine; 2015 Apr; 33(16):1959-67. PubMed ID: 25738814
[TBL] [Abstract][Full Text] [Related]
18. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.
Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S
Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661
[TBL] [Abstract][Full Text] [Related]
19. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
[TBL] [Abstract][Full Text] [Related]
20. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice.
Berg M; Gambhira R; Siracusa M; Hoiczyk E; Roden R; Ketner G
Vaccine; 2007 Apr; 25(17):3501-10. PubMed ID: 16914239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]